Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / Other Proteins

Recombinant Human HLA-E Protein, C-strep

Catalog #:   YHM00401 Specific References (50) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: E. coli
Accession: P13747
Protein length: Gly22-Trp295
Overview

Catalog No.

YHM00401

Expression system

E. coli

Species

Homo sapiens (Human)

Protein length

Gly22-Trp295

Predicted molecular weight

33.66 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

P13747

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

MHC class I antigen E, HLA class I histocompatibility antigen, alpha chain E, HLA-E, HLA-6.2, sHLA-E, HLAE

Data Image
  • SDS-PAGE
    SDS-PAGE for Recombinant Human HLA-E protein
References

Identification of cross-stage, cross-species malaria CD8+ T cell antigens., PMID:40502747

The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on Innate Immunity and COVID-19 Severity., PMID:40391199

The Novel HLA-E Allele, HLA-E*01:01:46, Identified in a Chinese Individual., PMID:40384027

A novel NKG2A alpaca nanobody targeting immune checkpoint blockade for the treatment of malignant melanoma., PMID:40370819

The Novel HLA-E*01:152 Allele Identified in African Populations Using Next-Generation Sequencing., PMID:40364544

Human Cytomegalovirus Antigen Presentation by HLA-G in Infected Cells., PMID:40347012

Structural Basis of SARS-CoV-2 Nsp13-Derived Peptide-Mediated NK Cell Activation., PMID:40331402

Optimization of hypo-alloimmunogenic multispecific CAR-T and SARS-CoV-2-specific T cells for off-the-shelf adoptive cell therapy., PMID:40321414

Overexpressing natural killer group 2 member A drives natural killer cell exhaustion in relapsed acute myeloid leukemia., PMID:40320412

Targeting the HLA-E-NKG2A axis in combination with MS-275 enhances NK cell-based immunotherapy against DMG., PMID:40296045

Allele and Haplotype Frequencies of 17 HLA-Related Loci in Shenzhen Chinese Population by Next-Generation Sequencing., PMID:40193066

Stratifying Multiple Sclerosis Susceptibility Risk: The Role of HLA-E*01 and Infectious Mononucleosis in a Population Cohort., PMID:40192262

Soluble HLA-E and Gastroesophageal Reflux Disease: A Novel Association‎., PMID:40147426

HLA-E/peptide complexes differentially interact with NKG2A/CD94 and T cell receptors., PMID:40085431

Identification and biophysical characterization of Plasmodium peptide binding by common African HLAs., PMID:40074802

Memory-like NK cell differentiation, inhibitory NKG2A blockade, and improved recognition via antibody or CAR engineering combine to enhance NK cell attack against multiple myeloma., PMID:40073259

Association between human leukocyte antigen E expression and outcomes in solid tumors: a systematic review and meta-analysis., PMID:40066089

Plasma proteins and herpes simplex virus infection: a proteome-wide Mendelian randomization study., PMID:39992613

Blebbisomes are large, organelle-rich extracellular vesicles with cell-like properties., PMID:39984653

CD94-driven in vitro expansion of highly functional adaptive NKG2C+ NKG2A- CD57+ NK cells from CMV+ healthy donors., PMID:39958331

Neutralizing IL-15 Inhibits Tissue-Damaging Immune Response in Ex Vivo Cultured Untreated Celiac Intestinal Mucosa., PMID:39937025

Nationwide multi-centric prospective study for the identification of biomarkers to predict the treatment responses of nivolumab through comprehensive analyses of pretreatment plasma exosome mRNAs from head and neck cancer patients (BIONEXT study)., PMID:39867897

Influence of HLA-B Leader (-21M/T) Dimorphism With Bw4/Bw6 Epitopes on Graft Versus Host Disease After Allogenic Haematopoietic Stem Cell Transplantation in North Indians., PMID:39865489

Natural Killer Cell Education in Women With Recurrent Pregnancy Loss., PMID:39853841

Prognostic value of immunosuppression scores in patients with esophageal squamous cell carcinoma: a multicenter study., PMID:39845968

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells., PMID:39815622

The Association of HLA-E Ligand and NKG2 Receptor Variation With Relapse and Mortality After Haploidentical Related Donor Transplantation., PMID:39798802

HLA-E/Mtb specific CD4+ and CD8+ T cells have a memory phenotype in individuals with TB infection., PMID:39790998

A Modular Self-Assembling and Self-Adjuvanting Multiepitope Peptide Nanoparticle Vaccine Platform to Improve the Efficacy and Immunogenicity of BCG., PMID:39757706

HLA-E: Immune Receptor Functional Mechanisms Revealed by Structural Studies., PMID:39753525

Single-cell profiling aligns CD56bright and cytomegalovirus-induced adaptive natural killer cells to a naïve-memory relationship., PMID:39742279

NK-cell cytotoxicity toward pluripotent stem cells and their neural progeny: impacts of activating and inhibitory receptors and KIR/HLA mismatch., PMID:39708357

Entry into the lytic cycle exposes EBV-infected cells to NK cell killing via upregulation of the MICB ligand for NKG2D and activation of the CD56bright and NKG2A+KIR+CD56dim subsets., PMID:39676862

Hypoimmunogenic CD19 CAR-NK cells derived from embryonic stem cells suppress the progression of human B-cell malignancies in xenograft animals., PMID:39664387

Emerging mutation in SARS-CoV-2 facilitates escape from NK cell recognition and associates with enhanced viral fitness., PMID:39652590

Targeting HLA-E in Lung Cancer: The Therapeutic Potential of IRF5-Engineered M1-Macrophage-Derived Exosomes., PMID:39623605

Hypoimmunogenic HLA-E Single Chain Inhibits Alloreactive Immune Responses., PMID:39621955

All-Atom Simulations Reveal the Effect of Membrane Composition on the Signaling of the NKG2A/CD94/HLA-E Immune Receptor Complex., PMID:39621690

Association Between NK Cell Genetic Variants and the Development of Long COVID Associated- and Prepandemic Small Fiber Neuropathy., PMID:39610330

Nutrient transporter pattern in CD56dim NK cells: CD16 (FcγRIIIA)-dependent modulation and association with memory NK cell functional profile., PMID:39606236

[Construction of a stable 4T1 cell line expressing UL19 by the PiggyBac transposon system]., PMID:39584339

NKG2C Sequence Polymorphism Modulates the Expansion of Adaptive NK Cells in Response to Human CMV., PMID:39581700

Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen., PMID:39578466

Targeting TSPEAR-AS2 suppresses tumor growth and interferon signaling in esophageal cancer., PMID:39567604

[Research progresses of Qa-1 restricted CD8+ regulatory T cells in the pathogenesis of infectious diseases]., PMID:39566528

The Novel HLA-E Allele, HLA-E*01:151, Identified in a Chinese Individual., PMID:39564865

Targeting the aminopeptidase ERAP enhances antitumor immunity by disrupting the NKG2A-HLA-E inhibitory checkpoint., PMID:39561763

IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells., PMID:39557863

Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy., PMID:39486805

Eight Novel HLA Class I Alleles Identified in Unrelated Haematopoietic Cell Donors and Recipients., PMID:39465562

Datasheet
$ 313
Product specifications
100 μg 313 1 mg 1629

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human HLA-E Protein, C-strep [YHM00401]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only